Bioequivalence of Two Empagliflozin 25 mg Immediate-Release Tablet Formulations Under Fasting Conditions in Healthy Mexican Subjects
Pharmaceuticals · 28.05.2026 · 19 (6) · 842
DOI: 10.3390/ph19060842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 28.05.2026. Verfasst von Porfirio de la Cruz Cruz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Doctorado Institucional en Ingeniería y Ciencia de Materiales (DICIM), de la Universidad Autónoma de San Luis Potosí (UASLP), Av. Sierra Leona No. 55…. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asofarma de México S.A. de C.V..
Abstract (Originalsprache)
Background/Objectives: Type 2 diabetes is a group of metabolic disorders whose pathophysiological outcome is sustained hyperglycemia. Several medications are available for the treatment. SGLT2 simultaneously inhibits glucose and sodium reabsorption in the renal proximal tubule, resulting in urinary glucose excretion. This study assessed the pharmacokinetic profiles of two empagliflozin 25 mg drug products under fasting conditions in healthy Mexican subjects to establish bioequivalence.
Methods
This was a randomized, open-label, two-way crossover, single-dose, prospective study with a 7-day washout period. Eligible subjects were healthy adult Mexican volunteers. The drugs were dosed orally, according to the randomization, after 10 h of fasting and 4 h before breakfast, with 250 mL of 10% glucose solution at room temperature. Serial blood samples were collected before and after dosing. Empagliflozin concentrations were analyzed using high-performance liquid chromatography–tandem mass spectrometry.
Results
A total of 32 subjects were enrolled, and 30 completed the study. Pharmacokinetic parameters Cmax, tmax, AUC0–t, AUC 0–∞, and t½ of empagliflozin for test and reference formulation, expressed as mean ± SD, were 578.28 ± 125.60 ng/mL, 2.72 ± 0.85 h, 4370.88 ± 769.50 ngh/mL, 4423.93 ± 776.02 ngh/mL, 7.62 ± 0.83 h, and 593.99 ± 156.78 ng/mL, 2.86 ± 1.00 h, 4313.24 ± 885.02 ngh/mL, 4368.04 ± 887.75 ngh/mL, and 7.61 ± 0.68 h, respectively. The 90% CI for Cmax, AUC0–t, and AUC 0–∞ were 98.30 [92.72–104.22], 101.72 [98.77–104.77], and 101.64 [98.73–104.63], respectively. Serious adverse events were not observed.
Conclusions
Our study demonstrated bioequivalence between the empagliflozin formulations tested in healthy subjects under fasting conditions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctorado Institucional en Ingeniería y Ciencia de Materiales (DICIM), de la Universidad Autónoma de San Luis Potosí (UASLP), Av. Sierra Leona No. 550, Col. Lomas 2da. Sección, San Luis Potosí C.P. 78210, Mexico.
- FS SCIENTIA PHARMA S.A. de C.V (Authorized Third Party), Av. Himno Nacional 1330, Jardín, San Luis Potosí C.P. 78270, Mexico.
- Asofarma de México S.A. de C.V. Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Ciudad de Mexico C.P. 05348, Mexico.
- Facultad de Ciencias Químicas, de la Universidad Autónoma de San Luis Potosí, Martínez #6, Av. Dr. Manuel Nava, Zona Universitaria, San Luis Potosí C.P. 78210, Mexico.
ORCID-Profile: José Trinidad Pérez Urizar
Förderung
- Asofarma de México S.A. de C.V.
Zitieren
APA
Cruz, P. C., Muñoz, A. M., Ávila, E. G. G., Piña, O. E. H., & Urizar, J. T. P. (2026). Bioequivalence of Two Empagliflozin 25 mg Immediate-Release Tablet Formulations Under Fasting Conditions in Healthy Mexican Subjects. Pharmaceuticals, 19(6), 842. https://doi.org/10.3390/ph19060842
Vancouver
Cruz PC, Muñoz AM, Ávila EGG, Piña OEH, Urizar JTP. Bioequivalence of Two Empagliflozin 25 mg Immediate-Release Tablet Formulations Under Fasting Conditions in Healthy Mexican Subjects. Pharmaceuticals. 2026;19(6):842. doi:10.3390/ph19060842
BibTeX
@article{Cruz2026,
author = {Cruz, Porfirio de la Cruz and Muñoz, Alberto Martínez and Ávila, Erika Gabriela Guido and Piña, Omar Emmanuel Hernández and Urizar, José Trinidad Pérez},
title = {Bioequivalence of Two Empagliflozin 25 mg Immediate-Release Tablet Formulations Under Fasting Conditions in Healthy Mexican Subjects},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {842},
doi = {10.3390/ph19060842}
}
EUVIMED